ViroLogic Announces the Promotion of Michael Bates, M.D., to Vice President of Clinical Research
June 22 2004 - 7:30AM
PR Newswire (US)
ViroLogic Announces the Promotion of Michael Bates, M.D., to Vice
President of Clinical Research SOUTH SAN FRANCISCO, Calif., June 22
/PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced
today that Michael Bates, M.D., has been promoted to the position
of Vice President, Clinical Research. Dr. Bates will manage the
Company's clinical programs and will report directly to Chairman
and CEO Bill Young. "Mike serves as a driving force of our clinical
research program and a key contributor to our physician education
initiatives, chairing Drug Resistance Forums and presenting to the
HIV physician community. He has made many important contributions
to ViroLogic as a collaborator with academic institutions and life
sciences companies," said Bill Young. "Mike is a true visionary who
firmly believes in personalized medicine. In his new role, Mike
will be able to build on his accomplishments in HIV and apply his
understanding of disease management and immunology as ViroLogic
expands into other diseases." Dr. Bates joined the Clinical
Research group at ViroLogic, Inc., as Medical Director in January
2001 and was promoted to Senior Director in 2003. Previously, Dr.
Bates served as Regional Medical Director/Medical Liaison for
Roche, focusing on virology. Dr. Bates completed his internship and
residency in Internal Medicine at the University of California, San
Francisco, before pursuing fellowship training in Cardiology at
Duke University in Durham, North Carolina, and in Infectious
Diseases at the University of Washington in Seattle, Washington.
About ViroLogic ViroLogic is a biotechnology company advancing
individualized medicine by discovering, developing and marketing
innovative products to guide and improve treatment of serious viral
diseases such as AIDS and hepatitis. The Company's products are
designed to help doctors optimize treatment regimens that lead to
better patient outcomes and reduced costs. ViroLogic's technology
is also being used by numerous biopharmaceutical companies to
develop new and improved anti-viral therapeutics and vaccines
targeted at emerging drug-resistant viruses. More information about
the Company and its technology can be found on its web site at
http://www.virologic.com/. Certain statements in this press release
are forward-looking. These forward-looking statements are subject
to risks and uncertainties and other factors, which may cause
actual results to differ materially from the anticipated results or
other expectations expressed in such forward-looking statements.
These risks and uncertainties include, but are not limited to,
whether ViroLogic successfully introduces new products, whether
others introduce competitive products, the risk that the Company's
products for patient testing may not continue to be accepted or
that increased demand from drug development partners may not
develop as anticipated, the risk that gross margins may not
increase as expected, the risk that ViroLogic may not continue to
realize anticipated benefits from its cost-cutting measures, the
timing of pharmaceutical company clinical trials, whether payors
will authorize reimbursement for its products, whether the FDA or
any other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in
automating its processes, whether intellectual property underlying
the Company's PhenoSense technology is adequate, whether licenses
to third party technology will be available, whether ViroLogic is
able to build brand loyalty and expand revenues, and whether
ViroLogic will be able to raise sufficient capital when required.
For a discussion of other factors that may cause ViroLogic's actual
events to differ from those projected, please refer to the
Company's most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as other subsequent filings with the
Securities and Exchange Commission. DATASOURCE: ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, +1-650-624-4164, or Web
site: http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles